Trials / Completed
CompletedNCT02552667
Efficacy and Safety of HCP1102 Capsule
Efficacy and Safety of HCP1102 Capsule : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 228 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and safety of HCP1102 capsule : A randomized, double-blind, active-controlled, multicenter phase 3 clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HCP1102+HGP0711Placebo | Coadministration of HCP1102 with HGP0711 Placebo for 4-week |
| DRUG | HCP1102Placebo+HGP0711 | Coadministration of HCP1102 Placebo with HGP0711 for 4-week |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2015-07-01
- Completion
- 2015-07-01
- First posted
- 2015-09-17
- Last updated
- 2015-09-17
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02552667. Inclusion in this directory is not an endorsement.